Apyx Medical Corporation will release Q1 2025 financial results on May 8 and conduct a conference call for discussions.
Quiver AI Summary
Apyx Medical Corporation has announced that it will release its financial results for the first quarter of fiscal year 2025 on May 8, 2025, before market opening. The company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results and answer questions, with participation available via phone and a live webcast. Apyx Medical, known for its proprietary helium plasma and radiofrequency technology marketed as Renuvion®, aims to enhance lives through innovative medical products. Its technologies, which include Renuvion and J-Plasma, are recognized for their effectiveness in cosmetic and surgical applications, supported by over 90 clinical publications. Interested parties can find additional information on the company’s website.
Potential Positives
- Apyx Medical is set to release its financial results for the first quarter of fiscal year 2025, which may provide insights into the company's financial health and performance.
- The upcoming conference call scheduled for May 8th allows for direct engagement with investors and stakeholders, fostering transparency and communication.
- The mention of over 90 clinical publications supporting the effectiveness of Renuvion and J-Plasma underscores the credibility and scientific backing of their products, enhancing their market position.
Potential Negatives
- Scheduling the conference call for an earnings report may prompt concerns about potential poor financial performance, especially if significant results are expected for Q1 fiscal year 2025.
- The focus on upcoming financial results without pre-release details may lead to market speculation and uncertainty regarding the company's current financial health.
- There is no mention of recent advancements or improvements in their technology, which could indicate stagnation in innovation within a competitive market.
FAQ
When will Apyx Medical release its financial results for Q1 2025?
Apyx Medical will release its financial results for the first quarter of fiscal year 2025 on May 8th, 2025.
How can I attend the Apyx Medical conference call?
To attend the conference call, dial 800-717-1738 or 646-307-1865 for international callers and use access code 63341.
What technology does Apyx Medical specialize in?
Apyx Medical specializes in helium plasma and radiofrequency technology, marketed as Renuvion® in cosmetic surgery.
Where can I find the live webcast of the conference call?
The live webcast of the conference call can be accessed on Apyx Medical's Investor Relations section of their website.
Who can I contact for investor relations inquiries?
For investor relations inquiries, contact Jeremy Feffer at LifeSci Advisors via phone at 212-915-2568 or email [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$APYX Hedge Fund Activity
We have seen 17 institutional investors add shares of $APYX stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NANTAHALA CAPITAL MANAGEMENT, LLC added 3,169,800 shares (+inf%) to their portfolio in Q4 2024, for an estimated $5,008,284
- GREENWOOD CAPITAL ASSOCIATES LLC removed 208,087 shares (-89.8%) from their portfolio in Q1 2025, for an estimated $285,079
- RATHBONES GROUP PLC removed 150,000 shares (-59.7%) from their portfolio in Q4 2024, for an estimated $237,000
- PERCEPTIVE ADVISORS LLC added 150,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $237,000
- KESTRA ADVISORY SERVICES, LLC removed 124,189 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $196,218
- SILVERBERG BERNSTEIN CAPITAL MANAGEMENT LLC added 75,337 shares (+13.2%) to their portfolio in Q1 2025, for an estimated $103,211
- RPG FAMILY WEALTH ADVISORY, LLC removed 75,250 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $118,895
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion ® , today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th.
Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will be archived for future reference.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
[email protected]
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion
®
in the cosmetic surgery market and J-Plasma
®
in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at
www.ApyxMedical.com